Nurix TherapeuticsNRIX
Recorded

Nurix Therapeutics UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration31 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

David DaiBiotech Analyst

Welcome back to the inaugural UBS Healthcare Conference here in London. My name is David Dai. I am a biotech analyst here at UBS, and now we have a session with Nurix Therapeutics. It is our great pleasure to have Arthur Sands, President and Chief Executive Officer, joining us with us here on the podium. Maybe a quick background for anybody who is interested story for Nurix. It is very interesting degrader story here. Nurix not only has some of the most interesting, I would say, degraders, but it has a lot of partnerships with Sanofi, Gilead, and most recently at Roche. We feel like those are a validation of their platform, of the programs. There is going to be quite a bit of updates over the next 6-12 months as well.

David DaiBiotech Analyst

Arthur, first question for you, helps understand a little more around the story for Nurix and the key programs we should be focusing on over the next 6-12 months.

Arthur SandsPresident and CEO

Yeah, sure. First off, thank you, David, for inviting us. We are happy to be part of the inaugural conference here in London. Nurix Therapeutics, we are focused on targeted protein degradation. Our lead program is in phase III, so we are working very diligently on expanding that program with Roche. That is our lead partner as well. It is around bexobrutideg, or Bexdeg for short, a degrader for BTK. The phase III launched in September. That is obviously a registrational study against pirtobrutinib head-to-head. We also have a phase II running as well, potential accelerated approval in third line plus. The phase III is in second line CLL. The phase II for accelerated approval is third line plus, so high unmet medical need population. Then if you go a little farther with Bexdeg, we are eager to expand into combinations as well.

Arthur SandsPresident and CEO

We have running our first combination trial with venetoclax, so combining BTK degradation with a well-characterized BCL2 inhibitor. Obviously, Roche being a perfect partner for that. We are also looking forward to expanding into antibody combinations with Bexdeg. Again, Roche has such a portfolio, so they were really a terrific partner for us, and we can talk more about the business terms of that deal later. In addition then, earlier in our pipeline, we just launched a phase I-B with our CBL-B inhibitor, which actually blocks degradation of proteins normally degraded by the E3 ligase CBL-B. It is an immuno-oncology target, and so we are in four different solid tumor indications, about 120 patients overall, plus launched a combination PD1 arm as well in that phase I-B. So that should be an exciting program to watch, very novel target in IO.

Arthur SandsPresident and CEO

We have the IRAK4 degrader, which is partnered with Gilead, that is completing phase I, and we look forward to data there from Gilead. A little farther back in the pipeline, we are looking to have an IND with a pan-BRAF degrader, which would be class I, II, and III BRAF mutants. We think it can expand the BRAF market potential and tumor scope, for which are all currently class I mutants only. We have many other programs earlier in our pipeline. It gives you an overview of the pipeline, but we are focused on targeted protein degradation, and I think we have built a really powerful platform.

David DaiBiotech Analyst

Yeah. Speaking of the platform, there are many targeted protein degradation companies out there. Maybe just help us understand a little more around your platform, how your platform is a bit different from others, and how you aim to drive, let us say, degrader discovery to an included development.

Arthur SandsPresident and CEO

Yeah. The broader area is called induced proximity, and of course, it can go in many directions. Targeted protein degradation is probably the largest area right now, but it is gaining a lot of interest, a lot more companies. One can cause molecules to be removed from the cell by grabbing them to other proteins. That is the RAS(ON) drug, for example, is an induced proximity drug from RevMed. There are many others that are evolving. What makes us unique is really the ability to identify novel chemical matter. That continues to be the bottleneck for all of induced proximity. These are largely novel targets, and finding ligands, chemical matter, that can actually bind to them, that is the starting point. Without that, you really cannot go anywhere. We have invested heavily in DNA-encoded libraries, which are very vast combinatorial libraries.

Arthur SandsPresident and CEO

In our collection, we have over 5 billion compounds, and we can screen any number of proteins, and have already, to find these novel ligands. That is how we have initiated many of our programs against novel targets. That is unique. It has taken us a long time to build that collection up. We have layered on an AI component to that. I know everyone talks about AI now, but we have actually been working at it for about eight or 10 years. Because we get such vast binding data sets out of this, we can use AI to predict new binders and new ligands that are not even in our library. It really expands into this virtual chemical space with a highly controlled data set. We are very excited about our platform. We think it is very differentiated.

David DaiBiotech Analyst

I mean, for sure. Based on the platform, you are able to generate multiple successful clinical candidates, including the BTK degrader, and that most recently has a partnership with Roche. Maybe help us to understand a little more around Roche's rationale to partner with Nurix, given the fact that they already have a BTK inhibitor that they are developing. How do you think about their current They have right now a lead into MS as well as CSU to be able to synergize with the BTK degrader platform as well.

Arthur SandsPresident and CEO

Yeah. Roche is really the perfect partner for us. We just entered that in June of this year, so it is a new collaboration, going extremely well. A little bit of metrics on the deal. It was a $700 million upfront payment, so a very substantial commitment from Roche into this big phase III oncology program in B-cell malignancy. So, although they do have a BTK inhibitor, fenebrutinib, in MS and autoimmune disease, they really did not have one for B-cell malignancies, which has become a centerpiece of all sorts of combination therapies, BTK as a target. So, they were very excited to have a degrader as a differentiated asset compared to all the BTK inhibitors, and we can talk about the advantages of degrading BTK versus inhibiting it. So this fit really well with their portfolio.

Arthur SandsPresident and CEO

The other metrics are, of course, it is like another $1.6 billion in milestones. Most importantly, it is a 50/50 co-development and co-commercialization in the U.S. They will take ex-U.S., we receive milestones and royalties ex-U.S., but we will have the product rights and commercialization co-co with them in the U.S. The costs are split 40/60, so 40% Nurix, 60% Roche. That is an important component because this is a very competitive area, requires global development, and Roche has that footprint, which we did not have. So there is natural synergies here between us, small company, and this huge multinational company, Roche. So good synergy, and I think it is really going to put Bexdeg as really at the forefront in the market when we get there.

David DaiBiotech Analyst

Right. That is really good to know, actually. The elephant in the room, of course, is going to be the STAT6 degrader, where most recently, Sanofi decided to discontinue the program from the partnership. Can you just help us understand a little more on Sanofi's decision to discontinue, and then, any way for you to be able to get the rights back?

Arthur SandsPresident and CEO

Well, first off, we were very disappointed with Sanofi's decision, and it came as quite a surprise to us. This is a program that started in 2019. We discovered the compound with them throughout the discovery process and the non-clinical development process. This just started phase I in September, so it was a new entrant to the space, but a lot of hopes around STAT6 as a target, which it is still, it is a great target. But in terms of what we can say, we really have very little information on the decision-making process. We are not part of the decision process, obviously. And what they cited was a non-clinical tox finding that made it inconsistent with their development criteria. So, we look forward to receiving the reports on this. We have not received the reports. We have not received any clinical data from the early parts of the trial.

Arthur SandsPresident and CEO

We think it requires a lot of analysis and attention, and we are currently not in a position, with very recent events, to be able to share more.

David DaiBiotech Analyst

Any thoughts in terms of what does it mean for the STAT6, the rights to the STAT6 degrader? Is there any way that you can get it back?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day